Ann: Resignation of Dr Michael Thurn & appointment of John Clark, page-239

@Dryasachip and @Peeteepoo We (PAA) need to get our stuff together and not just because we all want to become better off financially.

We have had tremendous support from the ALS/MND community and to fumble about now is a sad indictment on a very promising drug and company. Particularly when hope based on data and facts / results is so desperately needed given the failings of other drugs recently.

On the cusp of ODD approval, funding gap closure, trail application to HREC and much more, it seems a lot to ask of John while he still does his day job too.

I have given time but this is a new week and I expect new news that is of substance (other than1/4ly) that confirms we have moved beyond immediate damage control and have plans and backup plans.

I do wonder if there is an opportunity for the 'personal reasons' to be better managed between the BoD and now former CEO to see this move forward collectively. As @Dryasachip said, they make a good team. If this has anything to do with the CEO role, management of that role and expectations then I would have thought there has been some serious BoD & CEO sole searching, discussions and followed by robust / brave / forward looking actions to be in a position to set out the roadmap now for shareholders.

I waited to see if there was an announcement before open and seems disappointingly not.

adreamer.